GHRP 6 (5mg x 10 Vials) and CJC 1295 DAC (5mg x 10 Vials)
GHRP-6 & CJC-1295 DAC Peptide Combination
Research peptides / unlicensed medicinal productsGrowth hormone\u2013releasing peptide and GHRH analogue peptide combination (lyophilised vials)
Certifications
- No MHRA marketing authorisation identified for this combined product as a medicinal product in the UK.
- No specific CE marking as a medical device could be confirmed for this peptide bundle.
- Sold in the category of research chemicals/peptides, which typically fall outside the scope of licensed medicines regulation when marketed strictly for laboratory use.
- No MHRA marketing authorisation identified for this combined product as a medicinal product in the UK.
- No specific CE marking as a medical device could be confirmed for this peptide bundle.
- Sold in the category of research chemicals/peptides, which typically fall outside the scope of licensed medicines regulation when marketed strictly for laboratory use.
Growth hormone\u2013releasing peptide and GHRH analogue peptide combination (lyophilised vials)
Description
This product is a peptide combination bundle consisting of GHRP-6 and CJC-1295 DAC supplied as lyophilised powders in separate vials. Each bundle contains 10 vials of GHRP-6 (5 mg per vial) and 10 vials of CJC-1295 DAC (5 mg per vial). The product is marketed as a research peptide combination and is typically labelled for laboratory or research use only, not for human or veterinary administration.
Bnefits
- Provides separate, pre-weighed lyophilised vials of GHRP-6 and CJC-1295 DAC intended for research applications.
- Standard 5 mg per vial presentation for each peptide simplifies calculation of concentrations in experimental settings.
- Bundle format (10 vials of each peptide) facilitates multi-sample or repeated experimental use.
- Supplied as a dry (freeze-dried) powder to support stability during shipment and storage before reconstitution.
- Commonly used in pre-clinical and in vitro research exploring growth hormone–related signalling pathways (not for clinical or human use).
Indications
- Sold and labelled as research peptides for laboratory investigation only.
- Not indicated as a licensed treatment for any human or veterinary medical condition.
- Any clinical or performance-enhancement use would be outside authorised medicinal frameworks and may be unsafe or illegal.
Composition
- GHRP-6 peptide (Growth Hormone Releasing Peptide-6) – 5 mg per lyophilised vial (10 vials in the bundle).
- CJC-1295 DAC peptide (growth hormone–releasing hormone analogue with Drug Affinity Complex) – 5 mg per lyophilised vial (10 vials in the bundle).
- Lyophilised (freeze-dried) peptide powder in sterile vials; specific excipients, if any (e.g. mannitol, buffering agents), are not detailed in the public product listing.
Formulation
- Lyophilised peptide powders supplied in sterile glass vials.
- Each GHRP-6 vial contains 5 mg of peptide in dry form.
- Each CJC-1295 DAC vial contains 5 mg of peptide in dry form.
- Intended to be reconstituted with a suitable sterile diluent in research environments according to institutional protocols (not for injection into humans or animals).
Packaging
- 10 x 5 mg vials of GHRP-6 lyophilised peptide.
- 10 x 5 mg vials of CJC-1295 DAC lyophilised peptide.
- Total of 20 vials supplied as a combination bundle.
- Vials packaged in protective outer packaging suitable for shipment; detailed inner packaging configuration is not specified in the public listing.
- Typically labelled for research use only / not for human consumption (based on standard industry practice for such products).
Usage
- Product is intended for laboratory research use only and is not approved for human or veterinary administration.
- Handling, storage, reconstitution and disposal should follow institutional guidelines for research chemicals and peptides.
- Do not self-administer or use clinically; there is no validated dosing, safety or quality assurance for medicinal use in humans.
- Researchers should consult their own institutional protocols and safety data before working with peptide powders.
- Any further instructions regarding reconstitution volumes or handling should be taken from the product label or documentation provided directly by the supplier, if available.
Contraindications
- Not for human or veterinary use; self-administration or non-research use is contraindicated and may be unsafe.
- Should not be used as a substitute for licensed medicines or under unsupervised conditions.
- Individuals with any medical condition or taking other medications should not use this product outside of formal, regulated research frameworks.
- Contraindicated for use by pregnant or breastfeeding individuals, minors or anyone outside a controlled research setting.
Adverse Effects
- No formal safety profile is established for this specific commercial product in humans, as it is sold for research use only.
- Use outside research settings (e.g. self-injection) may pose serious, unpredictable risks including endocrine disruption, cardiovascular strain, metabolic effects and local injection reactions or infection.
- Illicit or unregulated peptide products may be mislabelled, contaminated or inaccurately dosed, increasing the risk of harm.
Storage Conditions
- Store in a cool, dry place according to any temperature recommendations on the vial or outer packaging.
- Keep vials protected from direct light and moisture.
- If specified by the supplier, refrigerate or deep-freeze lyophilised peptides to maintain stability; otherwise follow label guidance.
- Keep out of reach of unauthorised personnel, children and pets.
- Once reconstituted in a research setting, solutions should be handled using appropriate aseptic techniques and discarded in line with institutional policies.
Duration
Not applicable \u2013 this is a research peptide combination and not an authorised medicinal product with a defined treatment course.
Onset
Not applicable \u2013 no clinically approved or defined onset of effect, as the product is not authorised for therapeutic use.
